162 related articles for article (PubMed ID: 25348519)
1. Population pharmacokinetic analyses for BC-3781 using phase 2 data from patients with acute bacterial skin and skin structure infections.
Rubino CM; Xue B; Bhavnani SM; Prince WT; Ivezic-Schoenfeld Z; Wicha WW; Ambrose PG
Antimicrob Agents Chemother; 2015 Jan; 59(1):282-8. PubMed ID: 25348519
[TBL] [Abstract][Full Text] [Related]
2. Prediction of lefamulin epithelial lining fluid penetration after intravenous and oral administration using Phase 1 data and population pharmacokinetics methods.
Zhang L; Wicha WW; Bhavnani SM; Rubino CM
J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii27-iii34. PubMed ID: 30949708
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia.
Bhavnani SM; Zhang L; Hammel JP; Rubino CM; Bader JC; Sader HS; Gelone SP; Wicha WW; Ambrose PG
J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii35-iii41. PubMed ID: 30949705
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia.
Van Wart SA; Forrest A; Khariton T; Rubino CM; Bhavnani SM; Reynolds DK; Riccobene T; Ambrose PG
J Clin Pharmacol; 2013 Nov; 53(11):1155-67. PubMed ID: 23907740
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetics Study of Contezolid (MRX-I), a Novel Oxazolidinone Antibacterial Agent, in Chinese Patients.
Li L; Wu H; Chen Y; Yuan H; Wu J; Wu X; Zhang Y; Cao G; Guo B; Wu J; Zhao M; Zhang J
Clin Ther; 2020 May; 42(5):818-829. PubMed ID: 32389326
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials.
Rubino CM; Bhavnani SM; Moeck G; Bellibas SE; Ambrose PG
Antimicrob Agents Chemother; 2015; 59(6):3365-72. PubMed ID: 25824211
[TBL] [Abstract][Full Text] [Related]
7. Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia.
Riccobene TA; Khariton T; Knebel W; Das S; Li J; Jandourek A; Carrothers TJ; Bradley JS
J Clin Pharmacol; 2017 Mar; 57(3):345-355. PubMed ID: 27510635
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 Data.
Lakota EA; Van Wart SA; Trang M; Tzanis E; Bhavnani SM; Safir MC; Friedrich L; Steenbergen JN; Ambrose PG; Rubino CM
Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32340986
[TBL] [Abstract][Full Text] [Related]
9. Introduction: lefamulin and pharmacokinetic/pharmacodynamic rationale to support the dose selection of lefamulin.
Rodvold KA
J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii2-iii4. PubMed ID: 30949709
[TBL] [Abstract][Full Text] [Related]
10. Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia.
Zhanel GG; Deng C; Zelenitsky S; Lawrence CK; Adam HJ; Golden A; Berry L; Schweizer F; Zhanel MA; Irfan N; Bay D; Lagacé-Wiens P; Walkty A; Mandell L; Lynch JP; Karlowsky JA
Drugs; 2021 Feb; 81(2):233-256. PubMed ID: 33247830
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and Pharmacodynamic Analyses To Determine the Optimal Fixed Dosing Regimen of Iclaprim for Treatment of Patients with Serious Infections Caused by Gram-Positive Pathogens.
Lodise TP; Bosso J; Kelly C; Williams PJ; Lane JR; Huang DB
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133566
[TBL] [Abstract][Full Text] [Related]
12. Tedizolid population pharmacokinetics, exposure response, and target attainment.
Flanagan S; Passarell J; Lu Q; Fiedler-Kelly J; Ludwig E; Prokocimer P
Antimicrob Agents Chemother; 2014 Nov; 58(11):6462-70. PubMed ID: 25136028
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function.
Canut A; Isla A; Rodríguez-Gascón A
Int J Antimicrob Agents; 2015 Apr; 45(4):399-405. PubMed ID: 25700566
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of omadacycline dosing regimens in Chinese using population pharmacokinetic-pharmacodynamic analysis.
Wang K; Zhu Y; Xu F; Liu L; Liu L; Shi M; Nie J; Reinhart H; Liu J; Gao Y; Pu X
Eur J Pharm Sci; 2024 Apr; 195():106713. PubMed ID: 38295963
[TBL] [Abstract][Full Text] [Related]
15. Anti-infective Dosing for Obese Adult Patients: A Focus on Newer Drugs to Treat Methicillin-resistant Staphylococcus aureus Acute Bacterial Skin and Skin Structure Infections.
Pai MP
Clin Ther; 2016 Sep; 38(9):2032-44. PubMed ID: 27524636
[TBL] [Abstract][Full Text] [Related]
16. Target attainment of intravenous lefamulin for treatment of acute bacterial skin and skin structure infections.
van Os W; Zeitlinger M
J Antimicrob Chemother; 2024 Feb; 79(2):443-446. PubMed ID: 38174805
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and tolerability of lefamulin following intravenous and oral dosing.
Wicha WW; Prince WT; Lell C; Heilmayer W; Gelone SP
J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii19-iii26. PubMed ID: 30949704
[TBL] [Abstract][Full Text] [Related]
18. Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections.
Prince WT; Ivezic-Schoenfeld Z; Lell C; Tack KJ; Novak R; Obermayr F; Talbot GH
Antimicrob Agents Chemother; 2013 May; 57(5):2087-94. PubMed ID: 23422913
[TBL] [Abstract][Full Text] [Related]
19. Selection of dosing regimen with WST11 by Monte Carlo simulations, using PK data collected after single IV administration in healthy subjects and population PK modeling.
Fabre MA; Fuseau E; Ficheux H
J Pharm Sci; 2007 Dec; 96(12):3444-56. PubMed ID: 17854075
[TBL] [Abstract][Full Text] [Related]
20. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
